Absolute quantification of [ 11C]docetaxel kinetics in lung cancer patients using positron emission tomography

Clinical Cancer Research

Volumn 17, Issue 14, 2011, Pages 4814-4824

  Van Der Veldt, Astrid A M ^a   Lubberink, Mark ^a   Greuter, Henri N ^a   Comans, Emile F I ^a   Herder, Gerarda J M ^b   Yaqub, Maqsood ^a   Schuit, Robert C ^a   Van Lingen, Arthur ^a   Rizvi, S Nafees ^a   Mooijer, Martien P J ^a   Rijnders, Anneloes Y ^a   Windhorst, Albert D ^a   Smit, Egbert F ^a   Hendrikse, N Harry ^a   Lammertsma, Adriaan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; DEXAMETHASONE; DOCETAXEL; OXYGEN 15;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG TRANSPORT; DRUG UPTAKE; FEMALE; HUMAN; ISOTOPE LABELING; LUNG BLOOD FLOW; LUNG CANCER; MALE; NON INVASIVE PROCEDURE; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PREMEDICATION; PRIORITY JOURNAL; REPRODUCIBILITY; TREATMENT RESPONSE; TUMOR BLOOD FLOW;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBON RADIOISOTOPES; DEXAMETHASONE; FEMALE; HUMANS; KINETICS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PERFUSION; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; TAXOIDS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 79960394764     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2933     Document Type: Article

References (39)

1. Ganansia-Leymarie V, Bischoff P, Bergerat JP, Holl V. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents 2003;3:291-306. (Pubitemid 36758303)
2. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005;6:229-39. (Pubitemid 40450714)
3. Van Tilburg EW, Franssen EJ, Van der Hoeven JJ, et al. Radiosynthesis of [11C]docetaxel. J Label Compd Radiopharm 2004;47:763-77.
4. Van Tilburg EW, Mooijer MP, Brinkhorst J, Van der Meij M, Windhorst AD. Improved and semi-automated GMP-compliant radiosynthesis of [11C]docetaxel. Appl Radiat Isot 2008;66:1414-8.
5. Van der Veldt AA, Lammertsma AA, Hendrikse NH. [11C]docetaxel and positron emission tomography for noninvasive measurements of docetaxel kinetics. Clin Cancer Res 2007;13:7522-3.
6. 11C-labeled docetaxel in cancer patients. Eur J Nucl Med 2010;37:1950-8.
7. Hoekstra CJ, Stroobants SG, Hoekstra OS, Smit EF, Vansteenkiste JF, Lammertsma AA. Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography. Clin Cancer Res 2002;8:2109-15.
8. Ramanujan S, Koenig GC, Padera TP, Stoll BR, Jain RK. Local imbalance of proangiogenic and antiangiogenic factors: a potential mechanism of focal necrosis and dormancy in tumors. Cancer Res 2000;60:1442-8. (Pubitemid 30152019)
9. Shirakawa K, Takara K, Tanigawara Y, Aoyama N, Kasuga M, Komada F, et al. Interaction of docetaxel ("Taxotere") with human P-glycoprotein. Jpn J Cancer Res 1999;90:1380-6. (Pubitemid 30032078)
10. Latreille J, Gelmon KA, Hirsh V, Laberge F, Maksymiuk AW, Shepherd FA, et al. Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience. Invest New Drugs 1999;16:265-70.
11. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997;15:3149-55. (Pubitemid 27377507)
12. Salphati L, Benet LZ. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochem Pharmacol 1998;55:387-95. (Pubitemid 28070142)
13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
14. Jackson JR, Dembowski BS, Ehrenkaufer RL, McIntyre E, Reivich M. [15O]H2O, [15O]O2 and [15O]CO gas production, monitoring and quality control system. Appl Radiat Isot 1993;44:631-4.
15. Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS. Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med 2007;48:471-80. (Pubitemid 47604933)
16. Boellaard R, Van Lingen A, Van Balen SC, Hoving BG, Lammertsma AA. Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET. Eur J Nucl Med 2001;28:81-9. (Pubitemid 32120810)
17. Van der Veldt AA, Hendrikse NH, Harms H, Comans EF, Postmus PE, Smit EF, et al. Quantitative parametric perfusion images using oxygen- 15 labeled water and a clinical PET-CT scanner: test-retest variability in lung cancer. J Nucl Med 2010;51:1684-90.
18. Hermansen F, Rosen SD, Fath-Ordoubadi F, Kooner JS, Clark JC, Camici PG, et al. Measurement of myocardial blood flow with oxygen-15 labelled water: comparison of different administration protocols. Eur J Nucl Med 1998;25:751-9. (Pubitemid 28377039)
19. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control 1974;19:716-23.
20. Schwarz G. Estimating the dimension of a model. Ann Statist 1978;461-4.
21. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1-7. (Pubitemid 13129630)
22. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10. (Pubitemid 16134762)
23. Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-63. (Pubitemid 46630541)
24. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103. (Pubitemid 30324363)
25. Marre F, Sanderink GJ, De Sousa G, Gaillard C, Martinet M, Rahmani R. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996;56:1296-302. (Pubitemid 26080972)
26. Clarke SJ, Rivory LP. Clinical pharmacokinetis of docetaxel. Clin Pharmacokinet 1999;36:99-114.
27. Van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 2000;6:2598-603. (Pubitemid 30482093)
28. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62. (Pubitemid 40093472)
29. Kyle AH, Huxham LA, Yeoman DM, Minchinton AI. Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin Cancer Res 2007;13:2804-10. (Pubitemid 46788050)
30. Shalli K, Brown I, Heys SD, Schofield AC. Alterations of β-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J 2005;19:1299-301. (Pubitemid 41113729)
31. Germann UA. P-glycoprotein-a mediator of multidrug resistance in tumour cells. Eur J Cancer 1996;32A:927-44.
32. Badruddoja MA, Krouwer HG, Rand SD, Rebro KJ, Pathak AP, Schmainda KM. Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps. Neuro Oncol 2003;5:235-43. (Pubitemid 37265903)
33. McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 2000;68:356-66.
34. Kreis W, Budman DR, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 1997;79:196-202.
35. Wilson C, Scullin P, Worthington J, Seaton A, Maxwell P, O'Rourke D, et al.Dexamethasonepotentiatestheantiangiogenic activity ofdocetaxel in castration-resistant prostate cancer. Br J Cancer 2008;99:2054-64.
36. Van der Veldt AA, Luurtsema G, Lubberink M, Lammertsma AA, Hendrikse NH. Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance. Curr Pharm Des 2008;14:2914-31.
37. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Möhler M, Oberdorfer F, et al. Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 1998;39:1197-202. (Pubitemid 28326150)
38. Moehler M, Dimitrakopoulou-Strauss A, Gutzler F, Raeth U, Strauss LG, Stremmel W. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer 1998;83:245-53. (Pubitemid 28317803)
39. Inoue T, Kim EE, Wallace S, Yang DJ, Wong FC, Bassa P, et al. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm 1996;11:235-45. (Pubitemid 26313530)